Advertisement
Screener

Faeth Therapeutics, Inc. (FTH) Overview

Faeth Therapeutics, Inc. (FTH) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -2.84; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -131.45; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -3.62; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -3.91; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$7.50$10.58$14.94$21.10$29.78$42.052025-11-062026-11-06$5.49$11.35$23.46$48.50$100.27$207.272021-11-082026-11-06$5.49$13.41$32.77$80.05$195.56$477.752021-02-042026-11-06$5.49$13.41$32.77$80.05$195.56$477.752021-02-042026-11-06$5.49$13.41$32.77$80.05$195.56$477.752021-02-042026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$22.00
Previous close
$28.07
Change
-$6.07
Change (%)
-21.61%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

FTH
+163.07%
S&P 500
(m)

1 year

FTH
+193.93%
S&P 500
(m)

3 years

FTH
+75.44%
S&P 500
(m)

5 years

FTH
-87.05%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual -2.84

-131.53-99.31-67.09-34.88-2.6631 Mar 2025: estimate (m); actual -5.4531 Mar 2025(m)30 Jun 2025: estimate (m); actual -3.9130 Jun 2025(m)30 Sept 2025: estimate (m); actual -3.6230 Sept 2025(m)31 Mar 2026: estimate (m); actual -131.4531 Mar 2026(m)30 Jun 2026: estimate (m); actual -2.8430 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)-2.84(m)(m)
1 Jan 202631 Mar 2026(m)-131.45(m)(m)
1 Jul 202530 Sept 2025(m)-3.62(m)(m)
1 Apr 202530 Jun 2025(m)-3.91(m)(m)
1 Jan 202531 Mar 2025(m)-5.45(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual -16.72

-24.09-18.33-12.56-6.80-1.0431 Dec 2021: estimate (m); actual -1.3331 Dec 2021(m)31 Dec 2022: estimate (m); actual -1.5831 Dec 2022(m)31 Dec 2023: estimate (m); actual -1.2231 Dec 2023(m)31 Dec 2024: estimate (m); actual -24.0131 Dec 2024(m)31 Dec 2025: estimate (m); actual -16.7231 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)-16.72(m)(m)
1 Jan 202431 Dec 2024(m)-24.01(m)(m)
1 Jan 202331 Dec 2023(m)-1.22(m)(m)
1 Jan 202231 Dec 2022(m)-1.58(m)(m)
1 Jan 202131 Dec 2021(m)-1.33(m)(m)

Revenue vs. Earnings

USD

No complete retained periods.

No complete retained periods.

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$22.00(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$22.00High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning FTH

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending (m).

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
(m)
Profit margin
(m)
Return on assets · 12 month
(m)
Stock compensation expense · all employees · 12 months
(m)
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
(m)
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
451.25K
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-15.96%*
Total return · month
-17.05%*
Total return · quarter
20.89%*
Total return · half year
1.41%*
Total return · year to date
163.07%*
Total return · 1 year
193.93%*
Total return · 3 years
75.44%*
Total return · 5 years
-87.05%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
(m)
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

Faeth Therapeutics, Inc. Overview

View more →

(m)

(m)

SEC CIK
1829802
Industry (SIC)
2834 Pharmaceutical Preparations
Country of operation
United States
Business address
701 TILLERY STREET #12 #1010, AUSTIN, Texas, 78702, United States
Fiscal year end
1231
Phone
512-200-2982

Similar stocks

Stock NameCountryMarket CapPE Ratio
COLLEGIUM PHARMACEUTICAL, INC (COLL)United States$0.737B24.57
Design Therapeutics, Inc. (DSGN)United States$0.766B-12.78
Wave Life Sciences, Inc. (WVE)$0.780B-5.56
Olema Pharmaceuticals, Inc. (OLMA)United States$0.790B-5.35
Aclaris Therapeutics, Inc. (ACRS)United States$0.792B-9.78
Verastem, Inc. (VSTM)United States$0.706B-1.71
Nuvectis Pharma, Inc. (NVCT)United States$0.705B-17.53
GERON CORP (GERN)United States$0.803B-12.14
IRONWOOD PHARMACEUTICALS INC (IRWD)United States$0.694B5.37
Climb Bio, Inc. (CLYM)United States$0.683B-13.03